Dawson James Securities Announces the Completion of Approximately $11.5 Million Offering With CEL-SCI Corporation

BOCA RATON, FL--(Marketwired - October 28, 2015) - Dawson James Securities, Inc. in conjunction with CEL-SCI Corporation (NYSE MKT: CVM), announced today the closing of a best efforts offering of common stock and warrants at a combined price of $0.67 per unit for aggregate gross proceeds of approximately $11.5 million. Dawson James Securities Inc., acted as the sole placement agent for the offering. The warrants are immediately exercisable, expire in five-years and have an exercise price of $.067 per share.

"We are pleased to provide CEL-SCI with the capital required to continue their clinical trials and deliver on their overall strategic plan," said Robert D. Keyser, Jr., Dawson James' CEO. "The strength of the CEL-SCI story, fresh on the heels of our 2015 Small Cap Growth Stock Conference, garnered good interest from both institutional and retail investors," Keyser continued. CEL-SCI intends to use the net proceeds of the offering for its Phase 3 clinical trial, an ongoing Phase 1 study in HIV/HPV co-infected patients, other research and development, and general and administrative expenses. A shelf registration statement on Form S-3 declared effective by the Securities and Exchange Commission ("SEC") on July 8, 2014, a prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. A copy of the final prospectus relating to the offering may be obtained by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 1 N. Federal Highway, Suite 500, Boca Raton, FL 33432, Telephone: 561-391-5555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About CEL-SCI

CEL-SCI Corporation, a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company's core capabilities include: drug discovery, research, development and manufacturing of complex biological substances.

About Dawson James Securities

Dawson James Securities specializes in capital raising for small and microcap public and private growth companies primarily in the Life Science/Health Care, Technology and Consumer sectors and is a full service investment banking firm with research, institutional and retail sales, and execution trading and corporate services. Headquartered in Boca Raton, FL, Dawson James is privately held with offices in New York, California, Maryland and New Jersey. www.dawsonjames.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes", "expects", "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Member FINRA/SIPC.